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Anti-cancer treatment regimens can lead to both acute- and long-term myocardial
injury due to off-target effects. Besides, cancer patients and survivors are severely
immunocompromised due to the harsh effect of anti-cancer therapy targeting the bone
marrow cells. Cancer patients and survivors can therefore be potentially extremely
clinically vulnerable and at risk from infectious diseases. The recent global outbreak of
the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
and its infection called coronavirus disease 2019 (COVID-19) has rapidly become a
worldwide health emergency, and on March 11, 2020, COVID-19 was declared a
global pandemic by the World Health Organization (WHO). A high fatality rate has
been reported in COVID-19 patients suffering from underlying cardiovascular diseases.
This highlights the critical and crucial aspect of monitoring cancer patients and
survivors for potential cardiovascular complications during this unprecedented health
crisis involving the progressive worldwide spread of COVID-19. COVID-19 is primarily
a respiratory disease; however, COVID-19 has shown cardiac injury symptoms similar to
the cardiotoxicity associated with anti-cancer therapy, including arrhythmia, myocardial
injury and infarction, and heart failure. Due to the significant prevalence of micro- and
macro-emboli and damaged vessels, clinicians worldwide have begun to consider
whether COVID-19 may in fact be as much a vascular disease as a respiratory disease.
However, the underlying mechanisms and pathways facilitating the COVID-19-induced
cardiac injury in cancer and non-cancer patients remain unclear. Investigations into
whether COVID-19 cardiac injury and anti-cancer drug-induced cardiac injury in cancer
patients and survivors might synergistically increase the cardiovascular complications
and comorbidity risk through a “two-hit” model are needed. Identification of cardiac
injury mechanisms and pathways associated with COVID-19 development overlapping
with anti-cancer therapy could help clinicians to allow a more optimized prognosis and
treatment of cancer survivors suffering from COVID-19. The following review will focus
on summarizing the harmful cardiovascular risk of COVID-19 in cancer patients and
survivors treated with an anti-cancer drug. This review will improve the knowledge of
COVID-19 impact in the field of cardio-oncology and potentially improve the outcome
of patients.
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INTRODUCTION
For the past 40 years, the cancer survival rate has increased
considerably due to the improvement in cancer diagnosis and
treatment (1, 2). Unfortunately, anti-cancer drug therapy of
cancer patients can lead to serious cardiac injury adverse effects,
such as hypertension, arrhythmia, stroke, and heart failure (3).
These harmful anti-cancer drug-mediated cardiac injury adverse
effects are difficult to diagnose and prevent and can appear
years after the anti-cancer treatment is completed. Regrettably,
long-term anti-cancer drug-mediated cardiac injury can lead to
increased mortality of cancer survivors (4). Anti-cancer therapy
is very harsh and can adversely affect the bone marrow cells,
which can lead to a severe immune deficiency in cancer patients
and survivors (5). In particular, a delay of the adaptive response
with antibodies is observed in cancer patients and survivors, and
this can lead to an increase in the susceptibility to develop severe
infections caused by common viruses like influenza (6, 7).
A novel coronavirus named SARS-CoV-2 causing COVID-
19 appeared in Wuhan, China, toward the end of 2019.
Within a few months, SARS-CoV-2 spread all over the world
and was declared as a global pandemic by WHO on the
March 11, 2020. Initial studies showed that COVID-19 mainly
targeted and damage the respiratory system (8–11); however,
recent studies have reported that COVID-19 can also induce
cardiovascular complications, such as dysrhythmias, venous
thromboembolic events, myocarditis, myocardial injury, acute
myocardial infarction, and heart failure (12).
The myocardial injury associated with COVID-19 could harm
cancer survivors, who are already at high risk of suffering
from an anti-cancer therapy-induced cardiac injury (13). The
possible relation and overlap between the myocardial injury
mechanism of COVID-19 and the anti-cancer therapy-induced
cardiac injury is a major cause of concern in the clinic. In this
review, we will identify cardiac injury mechanisms and pathways
during COVID-19 development and the possible comorbidity
risk through a “two-hit” model cancer patients and survivors
are facing.
ANTI-CANCER THERAPY AND CARDIAC
INJURY
Anti-cancer Drugs Associated With
Cardiac Injury
While the anti-cancer therapy options available to cancer
patients have improved over the past decades, a rise in
Abbreviations: ACE, angiotensin-converting enzyme; ACE2, angiotensin-
converting enzyme 2; Ang(1–7), angiotensin 1–7; Ang II, angiotensin II;
ARDS, acute respiratory distress syndrome; BNP, B-type natriuretic peptide;
COVID-19, coronavirus disease 2019; cTnI, cardiac troponin I; ER, endoplasmic
reticulum; ERIG, endoplasmic reticulum–Golgi intermediate compartment;
ICI(s), immune checkpoint inhibitor(s); ICU, intensive care unit; LVEF, left
ventricular ejection fraction; NF-κβ, nuclear factor kappa-light-chain-enhancer;
RAS, renin angiotensin system; RIG-I, retinoic acid-inducible gene-I; ROS,
reactive oxygen species; SARS-CoV-2, severe acute respiratory syndrome
coronavirus 2; TLR, Toll-like receptors; TMPRSS2, type 2 transmembrane serine
protease; cTnI, cardiac troponin I; cTnT, cardiac troponin T; WHO,World Health
Organization.
cardiac adverse effects as a result of anti-cancer therapy has
emerged as a considerable cause for concern in cancer survivors.
Various types of chemotherapeutic anti-cancer drugs can induce
cardiac injury (14). Some of the most potent cardiotoxic
anti-cancer drugs belong to the anthracycline group, such
as doxorubicin (3). Anthracyclines can induce cardiac injury
through different intracellular mechanisms including oxidative
stress (15), mitochondrial dysfunction, reactive oxygen species
production (16), apoptosis (17), and myofibril damage (18).
Other chemotherapy drugs responsible for cardiac complications
include taxoids, antimetabolites, immune checkpoint inhibitors
(ICIs), alkylating agents, and tyrosine kinase inhibitors (19,
20). The antimetabolite 5-fluorouracil can interfere with the
nucleic acid function (21), and 5-fluorouracil treatment can
induce arrhythmia, silent myocardial ischemia, and congestive
heart failure in cancer patients (3). Therapy with ICIs has
been associated with atherosclerosis, venous thromboembolism,
vasculitis, Takotsubo syndrome, myocarditis, and hypertension
(22–24). The alkylating agent cyclophosphamide has both
cardiotoxic and immunosuppressive adverse effects (25), and
cyclophosphamide treatment can lead to arrhythmia, cardiac
tamponade, and congestive heart failure (3, 26). The tyrosine
kinase inhibitor sunitinib inhibits ribosomal S6 kinase activity
to induce cellular apoptosis (27), and sunitinib therapy can
induce cardiomyocyte death and hypertrophy, which can
lead to hypertension or, in the severe case, to congestive
heart failure (27).
Assessment of Cardiac Injury
Anti-cancer therapy-induced cardiac injury can be assessed by
imaging techniques and various circulating myocardial injury
biomarkers. Doppler echocardiography and echocardiographic
left ventricular ejection fraction (LVEF) are non-invasive
techniques used in the clinic to detect myocardial injury (28).
Cardiac injury can also be monitored through assessment of
relevant circulating biomarkers levels, such as cardiac troponin
I (cTnI) and B-type natriuretic peptide (BNP) (29). Cardiac
damages lead to an increase in cTnI, while the rise of left ventricle
wall stress leads to increased BNP levels (29). The “gold standard”
in the clinic to determine the onset and stage of cardiac injury is a
combination of LVEF assessment and determining the circulating
levels of cTnI and BNP.
Anti-cancer Therapy Can Lead
to Immunocompromised Status
in Cancer Patients
Cancer patients treated with anti-cancer drugs are at an increased
risk of developing infections and have fatal outcomes as a result
of immunodeficiency, due to the harsh effect of anti-cancer
therapy on the bone marrow cells (30). Cancer survivors tend to
have more frequently influenza infections and acute respiratory
infections than the general population (31). Moreover, childhood
cancer survivors are more likely to develop acute respiratory
disease after influenza infection due to their weak immunity
(7). Further to this, pre-existing cardiovascular diseases can
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aggravate in high-risk cancer survivors (32). The infection-
related complications observed in cancer survivors highlight that
they are at high risk from the new COVID-19 pandemic.
NOVEL GLOBAL PANDEMIC COVID-19
SARS-CoV-2 Transmission
The novel zoonotic RNA virus SARS-CoV-2 leading to COVID-
19 is from a large family of enveloped single-stranded zoonotic
RNA viruses (9). WHO has reported over 113 million COVID-19
cases and over 2.5 million COVID-19-related deaths worldwide
(by March 1, 2021). SARS-CoV-2 is transmitted human-to-
human by indirect or direct contact through mucus membranes
(i.e., mouth, eyes, or nose). Transmission is primarily mediated
through airborne microparticles encapsulating the SARS-CoV-
2 viral inoculum being inhaled in the nasal cavity, followed by
aspiration of the SARS-CoV-2microparticles into the lung, where
SARS-CoV-2 then triggers the viral infection (33).
COVID-19 Symptoms
SARS-CoV-2 infection can induce systematic and respiratory
disorders (34). The most common symptoms of COVID-19
are high fever, consistent dry cough, and loss of smell and
taste sense (10). Several COVID-19 patients showed symptoms
of viral pneumonia, such as sore throat, fatigue, and myalgia
(11). The most serious cases of SARS-CoV-2 infections have
fatal outcomes. The period from the onset of symptoms to
death ranges from 6 to 41 days, depending on the vulnerability
of the patient (35).
COVID-19 was first considered as a respiratory disease, due
to the acute respiratory distress syndrome (ARDS). Indeed,
in critical COVID-19 cases, patients suffer from dyspnoea,
RNAaemia (i.e., detection of SARS-CoV-2 RNA in blood
serum), and hypoxemia, and ground-glass opacities have been
observed in sub-pleural regions of both of their lungs (36, 37).
However, recent studies have shown that COVID-19 can cause
inflammation-associated complications in other systems, such as
the cardiovascular, cerebral, and gastrointestinal systems (10).
COVID-19 Risk Factors
The key prognostic risk factors in patients with COVID-
19 include obesity, metabolic syndrome, diabetes mellitus,
hyperglycaemia, coagulopathy, cigarette smoking, previous
cardiovascular diseases, hypertension, previous cardiotoxic
anticancer therapies, and active cancer. Furthermore, in
cancer patients infected with COVID-19, the additional
risk factors include various active anti-cancer treatments,
such as chemotherapy, radiotherapy, and bone marrow or
stem cell transplants (24). The most consistent predictors of
poor outcomes of COVID-19 are age and gender (Figure 1).
A higher incidence of fatalities is observed in the elderly
COVID-19 patients compared to younger patients. The exact
mechanisms involved are yet to be discovered; however, the
increased prevalence of frailty and cardiovascular disease in
the elderly population is thought to be due to pre-existing
endothelial dysfunction and loss of endogenous cardioprotective
mechanisms (38). Gender also plays an important factor in
the clinical outcome following the contraction of COVID-
19. Regardless of their age, women are less susceptible to
severe infection outcomes, and fewer women are dying of
COVID-19-related complications than age-matched males.
The gender-associated difference in COVID-19 outcome is
thought to be linked to two key mediators of viral attachment
to cell membranes, namely, the angiotensin-converting enzyme
(ACE) 2 receptor (ACE2) for the spike protein of coronaviruses,
and the type 2 transmembrane serine protease (TMPRSS2),
which cleaves the spike protein and thereby facilitates the
attachment and fusion of the virus to cell membranes (39, 40).
In particular, the ACE and ACE2 expression levels and the
resulting ACE/ACE2 activity ratio are important factors for
COVID-19 infection outcome. ACE has pro-inflammatory and
pro-oxidant effects, whereas ACE2 has anti-inflammatory and
antioxidant effects (41, 42). The ACE/ACE2 activity ratio has
shown to be lower in serum samples of females compared to male
serum samples, and the lower ACE/ACE2 activity ratio could
be one of the factors that protect female COVID-19 patients
from developing severe complications (42). In older COVID-19
patients, the worse outcome has been attributed to the presence
of lower ACE2 levels compared to younger patients and thus the
subsequent upregulation of pro-inflammatory pathways through
angiotensin II (43).
COVID-19 Mechanism of Action
SARS-CoV-2 Transmission and Replication
SARS-CoV-2 is transmitted through the surface mucus
membranes in the host human cells, where the viral surface spike
protein binds to the cellular entry receptor ACE2 facilitating
viral entry into host cells (44). The cellular serine protease
TMPRSS2 cleaves the SARS-CoV-2 spike protein, thus allowing
the attachment and fusion of SARS-CoV-2 virus to the host cell
membrane and release of viral RNA in the host cell cytosol (40).
The viral RNA is translated in the endoplasmic reticulum by
the Golgi complex to produce more virions contained in double
membrane vesicles, which are released in the extracellular matrix
by exocytosis (45, 46) (Figure 2).
ACE2 Receptors Involved in Cardiac Function
ACE2 is highly expressed in lung, heart, and kidneys, and is a
key negative regulator of the renin angiotensin system (RAS)
through angiotensin II expression adjustments (47). SARS-
CoV-2 downregulates ACE2 expression by binding to ACE2
receptors (47). In a murine model, the decrease in ACE2
promoted an increase of angiotensin II level in alveolar cells,
which causes an increase of pulmonary vascular permeability
leading to pulmonary oedema and lung dysfunction (48).
Another study demonstrated that the loss of ACE2 promoted the
upregulation of hypoxia-inducible gene (i.e., BNIP3 and PAI-1)
expression in a murine model (49). All in all, the increase of
vascular permeability, hypoxia, and hyper-inflammation caused
by COVID-19 leads to ARDS, which is characterized by
pulmonary oedema (50).
The ACE2 receptors are also expressed in vascular
endothelium cells (51) and are key regulators of cardiovascular
homeostasis (52). Knockout of the ACE2 gene expression in
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FIGURE 1 | Overview of the COVID-19 risk factors and complications observed in COVID-19 patients leading to cardiac injury (figure created with Biorender.com).
murine hearts leads to an increase in angiotensin II levels and
severe diminution of cardiac contractility when compared
to wild-type mice, thus indicating that ACE2 receptors are
essential regulators of cardiac function and ACE2 loss induces
myocardial injury (49).
SARS-CoV-2 Triggered Immune Response
A viral infection is followed by the innate and adaptive responses
of the immune system. In the innate response, the viral RNA
is considered as a pathogen-associated molecular pattern and
is detected by the pattern recognition receptors. Viral RNA is
detected by the Toll-like receptors (TLR) in the endosomes,
and retinoic acid-inducible gene-I (RIG-I)-like receptors detect
the viral RNA in the cytoplasm (53). This innate response is
followed by the adaptive immune response by T-cells, which
play a key role in viral infection by regulating the balance
between the risk of autoimmunity and overactive inflammation.
CD4+ T-cells promote the production of antibodies specific
to the virus by activating T-dependent B-cells. In addition, T-
helper cells produce pro-inflammatory cytokines via the nuclear
factor kappa-light-chain-enhancer (NF-κβ) signaling pathway
and regulatory T-cells maintain the homeostasis of the immune
system. Finally, the cytotoxic CD8+ T-cells exterminate the
infected cells through antigen recognition (53–55) (Figure 3).
In patients with COVID-19, several studies have highlighted
the increase of neutrophils, leukocytes, and lymphopenia.
The neutrophil–lymphocyte ratio is a marker of systemic
inflammation due to an infection and is increased during
COVID-19 (55). In a cohort study including 452 patients in
Wuhan, China, an increase of interleukins IL-2, IL-6, IL-8, IL-
10, and NF-κβ was observed in COVID-19-infected patients
(55). IL-6 levels are increased during infection and IL-6 is a
significant modulator of the cytokine storm. Moreover, there
is a significant increase in the IL-6 levels in severe cases of
COVID-19, when compared to mild COVID-19 cases (55, 56). A
correlation between the severity of COVID-19 and the increase
of pro-inflammatory cytokines have been observed in COVID-
19 patients (57). COVID-19 damages specific tissue, which can
aggravate the cytokine production, leading to the development
of a cytokine storm, characterized by an excessive production of
pro-inflammatory cytokines and the recruitment of macrophages
and granulocytes. The cytokine storm can lead to more damage
in lung tissue, ARDS (58), and myocardial injury (59).
COVID-19 and Cardiac Injury
Cardiac complications in patients infected by SARS-CoV-2
have been reported, particularly in severe COVID-19 cases
(60, 61). Thrombotic complications, such as microvascular
thrombosis, venous thromboembolic disease, and stroke, have
been identified in severe COVID-19 cases (62). The mechanism
of action is thought to be SARS-CoV-2 invading ACE2 receptors
expressed on the surface of endothelial cells (63). The subsequent
endothelial inflammation process in COVID-19 patients induces
a dysfunction of the endothelial homeostasis, and this can lead
to severe and life-threatening (micro)thrombotic complications,
such as pulmonary embolism, deep vein thrombosis, and stroke
(64, 65). Further to this, ACE2 receptors are highly expressed in
the heart and can lead to ACE2-dependent myocardial infarction
(66). COVID-19 has also been shown to cause cardiac injury by
directly targeting the cardiac cells (67, 68).
In a cohort of 416 COVID-19 patients, cardiac injury was
determined by the assessment of serum cardiac markers levels,
including high-sensitivity troponin I, and by measurement of
abnormalities in electrocardiography readings. All cardiac injury
trials in these COVID-19 patients were similar to those observed
during myocardial ischemia. This cohort study showed a very
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FIGURE 2 | The SARS-CoV-2 pathway in the host cells. The spike protein of the virus binds to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and is
cleaved by the type 2 transmembrane serine protease (TMPRSS2). This allows entry into the host cell by endocytosis. Following the entry of SARS-CoV-2, viral RNA is
released into the cytoplasm and replicated. Viral RNA is translated by the endoplasmic reticulum (ER) by Golgi complex and form the endoplasmic reticulum–Golgi
intermediate compartment (ERIG). Viral RNA enters into ERIG by budding to form novel virions. These virions are released from the infected cells by exocytosis. The
ACE2 receptor is a negative regulator of the renin angiotensin system (RAS) and converts angiotensin II (Ang II) into angiotensin 1–7 [Ang(1–7)]. The downregulation of
the RAS allows to maintain the cardiovascular homeostasis (figure created with Biorender.com).
high mortality rate of 51% among COVID-19 patients with
cardiac injury complications. The study compared biomarkers
levels and radiographic findings in 82 COVID-19 patients with
cardiac injury with 334 COVID-19 patients without cardiac
injury. According to their comparison, COVID-19 patients with
cardiac injury had a significantly higher mortality risk than
COVID-19 patients without cardiac injury (67). In another
cohort study, 7.2% of the 138 hospitalized COVID-19 patients
developed an acute cardiac injury after being infected by
SARS-CoV-2, and these patients represented 22.2% of the
COVID-19 patients admitted to the intensive care unit (ICU).
The results of this study suggest that the manifestation of
acute cardiac injury correlates to an imparted outcome in
COVID-19 patients (69).
The cardiac injury mechanisms of action involved during
COVID-19 infection remain unclear; however, it could be due
to altered expression of ACE2 receptors and involvement of
the cytokine storm (70, 71). Additionally, the myocardial injury
could be caused by cardiac stress induced by hypoxia from ARDS
(72). In two independent single-patient clinical case reports
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FIGURE 3 | Overview of the immune response to COVID-19. The proteins on SARS-CoV-2 membrane are recognized as pathogen-associated molecular pattern by
the pattern recognition receptors (PRRs), such as Toll-like receptors (TLR) and retinoic acid-inducible gene-I (RIG-I)-like receptors. This recognition leads to the
activation of T-cells, which differentiate in CD4+ T-cells, CD8+ T-cells, and T-helper cells that induce, respectively, the production of antibodies by B-cells, the deaths of
infected cells, and the cytokine production, such as interleukins IL-2 and IL-6. Moreover, SARS-CoV-2 invasion leads to the recruitment of neutrophils and
macrophage and induce a lymphopenia. The increase of neutrophils and macrophages associated with the cytokine production leads to a hyperinflammation called
the cytokine storm. This cytokine storm leads to acute respiratory distress syndrome (ARDS) and myocardial damage. Green arrows refer to activating effects, orange
arrows refer to recruitment effects, and the red lines refer to inhibiting effects (figure created with Biorender.com).
from China, the individual patients infected by SARS-CoV-
2 were hospitalized and were suffering from both pneumonia
and cardiac symptoms. The COVID-19 patients had elevated
troponin T level, abnormal echocardiography, decreased LVEF,
and elevated IL-6 levels, which could indicate a possible ongoing
cytokine storm. The prognosis of clinicians was that the patients
were suffering from fulminant myocarditis induced by SARS-
CoV-2 (73, 74). Other studies have suggested that myocarditis
represents 7% of deaths due to COVID-19 complications (75).
However, most of these reports are based on assumptions and are
not based on confirmed myocarditis diagnoses (76).
Studies have shown that COVID-19 patients suffering from
severe complications are affected by arrhythmia (69, 77). Indeed,
viral infections like COVID-19 are associated with myocardial
inflammation, which can lead to cardiac arrhythmia (70).
Other studies have observed an increase of D-dimer levels and
fibrin degradation products in COVID-19 patients, and these
features are known as indicators of disseminated intravascular
coagulation and pulmonary embolism (70, 78). A report based
on 106 pulmonary CT angiograms from COVID-19 patients
showed that 30% of the patients had acute pulmonary with
high D-dimer threshold and argued that this could be due
to an increase in the blood coagulation level following the
cytokine storm (79).
COVID-19 AND CANCER PATIENTS AND
SURVIVORS
Increased COVID-19 Complications
and Comorbidity in Cancer Patients
and Survivors
Cancer patients have an estimated two-fold increased risk of
contracting SARS-CoV-2 compared to the general population
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(80). In a cohort study of 1,590 Chinese patients suffering
from COVID-19, it was noted that 1.13% of them were
cancer patients/survivors, which is higher than the overall
0.29% cancer incidence in China. Among the 18 cancer
survivors, 4 of them had completed chemotherapy or surgery
the past month, 12 were cancer survivors in routine follow-
up, and 2 did not report their cancer history. This study
showed that COVID-19 patients with recently completed anti-
cancer therapy were those experiencing the most severe
COVID-19 complications, and some of these patients
died before the onset of COVID-19 treatment. Therefore,
recent completion of anti-cancer therapy seems to be an
important risk factor for developing severe complications during
COVID-19 infection (81).
In another study from Wuhan, China, 28 cancer patients
with COVID-19 were monitored closely for complications: 54%
of them developed severe complication, 21% were admitted to
ICU, 38% were considered to be in a life-threatening condition,
and 28% died as a result of their complication. The cancer
survivors started with developing the most common symptoms
of COVID-19 consisting of a high fever and a consistent cough;
however, the COVID-19 complications escalated quickly and
they also developed anamia and hypoproteinaemia, leading
to a reduction of immunocompetence and increasing the
risk of developing respiratory complications. The last two
symptoms, anamia and hypoproteinaemia, are not common in
COVID-19 patients without any anti-cancer therapy history.
COVID-19 patients with a previous anti-cancer therapy history
seem to develop dyspnoea at an earlier stage compared to
COVID-19 patients without previous cancer history. This study
strongly indicates that cancer patients and survivors might
have a higher risk of developing viral infection with severe
complications due to their immunocompromised status (82).
Please refer to Table 1 for an overview of comorbidities
and complications observed in COVID-19 patients suffering
from cardiac injury identified in the studies included in
this review.
Anti-cancer Drug-Induced Cardiovascular
Injury Might Increase COVID-19
Complication Risks
Certain anti-cancer drugs can cause severe cardiotoxicity
through increased fibrosis, oxidative stress, apoptosis,
and necrosis in myocardial cells, thus increasing the risk
of cardiomyopathies and heart failure. The anti-cancer
drug-induced cardiotoxicity could exacerbate COVID-19-
mediated cardiac injury and dysfunction. These drugs include
anthracyclines (83, 84), tyrosine kinase inhibitors (85, 86),
proteasome inhibitors (87), human epidermal growth factor
receptor 2 blocking antibodies (88), and ICIs (89). The
intracellular mechanisms involved during anthracycline-induced
injury in cardiomyocytes include (a) binding to nuclear and
mitochondrial DNA and interfering with replication, (b)
inhibiting the TOPO II enzyme leading to the damaged DNA
during the cell replication process, (c) disturbing the Ca2+
influx into the cell, (d) disruption of Ca2+ homeostasis in
the mitochondria leading to an increase in reactive oxygen
species (ROS) production and oxidative stress, (e) contractile
dysfunction due to decreased expression of the Ca2+ pump
SERCA2a in the sarcoplasmic reticulum, and (f) preventing the
release of iron from ferritin and facilitating the reduction of
anthracycline–Fe3+ complexes leading to ROS production. ROS
production, DNA damage, and contractile dysfunction can all
lead to cellular apoptosis (3). Figure 4 describes the molecular
mechanisms involved during anthracycline treatment-induced
injury in cardiomyocytes and link them to the SARS-CoV-2
infection pathway.
A clinical study assessed the outcome of underlying
cardiovascular complications in 138 hospitalized COVID-
19 patients in Wuhan, China, with underlying cardiac
comorbidities: 58% patients were suffering from hypertension,
22% patients had diabetes, and 25% already had a cardiovascular
disease (69). Similar findings were published in another report,
where 416 hospitalized COVID-19 patients were suffering
from co-existing cardiovascular diseases: 60% patient had
hypertension, 24% patients suffered from diabetes, 29% patient
had coronary heart disease, while 15% patients had suffered
chronic heart failure (67). According to the National Health
Commission of the People’s Republic of China, 35% of COVID-
19 patients had hypertension and 17% suffered from coronary
heart disease prior to their COVID-19 development (69). These
studies indicate that patients with myocardial injury due to
underlying cardiovascular diseases are more likely at risk to
develop severe complications as a result of SARS-CoV-2 infection
(67, 69, 71). Further to this, anti-cancer drugs can trigger late-
term cardiovascular adverse effects, such as hypertension, cardiac
dysfunction, thromboembolic events, and ischemia heart disease,
and these cardiovascular complications are considered high risk
factors of developing severe complications during COVID-19
infection in cancer survivors (90).
Cancer patients have a high risk of venous thromboembolism,
particularly cancer patients treated with pro-inflammatory
drugs and radiotherapy (91, 92). Therapy with anti-cancer
drugs has also been associated with venous thromboembolism,
which potentially could exacerbate the COVID-19-induced
intravascular coagulative damages. These anti-cancer drugs
lined with venous thromboembolism adverse effects include
anti-VEGF therapies, tyrosine-kinase inhibitors, platinum-
based drugs, proteasome inhibitors, hormonal therapy,
and immunomodulators (93). Cancer patients initiating or
continuing ICI therapy are facing a dilemma during the
COVID-19 pandemic. A potential COVID-19 infection is
characterized by mild to severe inflammation of the lungs
and other organs. Both the ICI-induced immune-related
adverse events and the COVID-19-caused inflammation include
unrestrained immune and cytokine activation; therefore, ICI
therapy could impact the course of COVID-19 and worsen
the outcome (94). Cancer patients treated with ICIs are at
increased risk of developing myocarditis, and recently, there
have been increasing reports that COVID-19 is also associated
with the development of myocarditis, with inflammatory
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Comorbidities and cancer type (if specified) COVID-19 complications
Huang et al. (10) 41 (32% ICU) 73.00% 49 Diabetes (20%), Hypertension (15%), Cardiovascular
diseases (15%), Chronic obstructive pulmonary disease
(2%), Malignancy (2%), Chronic liver disease (2%).
ARDS (29%), RNAaemia
(15%), Acute cardiac injury
(12%), Secondary infection
(10%), Acute kidney injury
(7%), Shock (7%).
Qin et al. (55) 452 52.00% 58 Hypertension (29.5%), Tuberculosis (19.7%), Diabetes
(16.4%), Cardiovascular disease (5.9%), Malignant tumor
(3.1%), Chronic obstructive pulmonary disease (2.6%),
Cerebrovascular disease (2.4%), Chronic kidney disease




12 (all dead) 75.00% 73 Coronary heart disease (50%), Arterial hypertension (25%),
Chronic obstructive pulmonary disease (25%), Obesity
(25%), Diabetes (25%), Bronchial asthma (25%), Nicotine
abuse (16.7%), Atrial fibrillation (16.7%), Chronic kidney
disease (16.7%), Parkinson disease (16.7%), Peripheral
artery disease (8.3%), Granulomatous pneumopathy (8.3%),
Dementia (8.3%), Epilepsy (8.3%), Trisomy 21 (8.3%),




Shi et al. (67) 416 49.30% 64 Hypertension (30.5%), Diabetes (14.4%), Coronary heart
disease (10.6%), Cerebrovascular disease (5.3%), Chronic
heart failure (4.1%), Chronic renal failure (3.4%), Chronic
obstructive pulmonary disease (2.9%), Cancer (2.2%),







Han et al. (68) 273 (5.5% ICU) 35.53% 58.95 – –
Wang et al. (69) 138 (26% ICU) 54.30% 56 Hypertension (31.2%), Cardiovascular disease (14.5%),
Diabetes (10.1%), Malignancy (7.2%), Cerebrovascular
disease (5.1%), COPD (2.9%), Chronic kidney disease
(2.9%), Chronic liver disease (2.9%), HIV infection (1.4%).
ARDS (19.6%), Arrhythmia
(16.7%), Shock (8.7%),
Acute cardiac injury (7.2%),
Acute kidney injury (3.6%).
Zeng et al. (73) 1 100.00% 63 Allergic cough for 5 years. Previous smoking history.





Hu et al. (74) 1 100.00% 37 Markers of myocardial injury elevated. Fulminant myocarditis with
cardiogenic shock and
pulmonary infection.
Liu et al. (77) 137 44.50% 57 Chronic diseases (17.5%), Diabetes (10.2%), Hypertension
(9.5%), Cardiovascular disease (7.3%), Chronic obstructive
pulmonary disease (1.5%), Malignancy (1.5%).
84% of patients have elevated C-reactive protein levels.
–












Chronic obstructive pulmonary disease, Diabetes,
Hypertension, Coronary heart disease, Cerebrovascular
disease, Viral hepatitis type B, Malignant tumor, Chronic
kidney disease, and Immunodeficiency.
Cancer types: 17 patients with solid cancers including lung
cancer and breast cancer), and 1 patient with lymphoma.
–
Zhang et al. (82) 28 (21.4% ICU) 60.70% 65 Diabetes (14.3%), Chronic cardiovascular and
cerebrovascular disease (including hypertension and
coronary heart disease) (14.3%), Chronic liver disease
(including chronic hepatitis B and cirrhosis) (7.1%). Chronic
pulmonary disease (including chronic obstructive pulmonary
disease and asthma) (3.6%).
82% of patients have elevated C-reactive protein levels.
Cancer types: Lung (25%), esophagus (14.3%), Breast
(10.7%), Laryngocarcinoma (7.1%), Liver (7.1%), Prostatic
(7.1%), Cervical (3.6%), Gastric (3.6%), Colon (3.6%),
Rectum (3.6%), Nasopharynx (3.6%), Endometrial (3.6%),






ARDS, acute respiratory distress syndrome.
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FIGURE 4 | Molecular mechanisms involved during anthracycline (Hexagonal box with “A”) treatment and SARS-CoV-2 infection in cardiomyocyte leading to injury.
Anthracycline can bind to nuclear and mitochondrial DNA and interfere with the cell replication process. The TOPO II enzyme can be inhibited by anthracycline,
leading to the damaged DNA during cell replication. Anthracycline can also disturb the Ca2+ influx into the cell. The disruption of Ca2+ homeostasis by anthracycline in
the mitochondria leads to an increase of reactive oxygen species (ROS) production and oxidative stress. Moreover, the expression of the Ca2+ pump SERCA2a in the
sarcoplasmic reticulum is decreased by anthracycline, which induces contractile dysfunction. Anthracycline can also prevent the release of iron from ferritin and
facilitate the reduction of anthracycline–Fe3+ complexes leading to ROS production. Combined, these anthracycline mechanisms lead to increased ROS production,
DNA damage, and contractile dysfunction, which leads to cellular apoptosis. Please refer to Figure 2 legend for a detailed description of the SARS-CoV-2 pathway
(figure created with Biorender.com).
cellular infiltrate similar to that seen in ICI-induced myocarditis
(95, 96).
Comorbidity Could Follow a “Two-Hit”
Model
Cancer survivors can unfortunately suffer from subclinical
myocardial injury due to adverse effect from their anti-cancer
therapy (97). A study showed that 65% of cancer survivors treated
with anthracycline ended with subclinical cardiac injury (98).
Patients treated with anthracycline may suffer from subclinical
left ventricle dysfunction, which can possibly lead to clinical
cardiomyopathy (99). The cardiac reserve can be defined as
“the increase in cardiac function from rest to peak exercise.”
In cancer survivors, anthracycline treatment reduces the cardiac
reserve, and this parameter can be used as a marker of subclinical
cardiac myocardial injury (90). Several reports have concluded
that the risk of developing cardiac dysfunction increases over
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the years after completion of anthracycline cancer treatment, and
in the most severe adverse effect cases, heart failure is observed
(100–103).
The subclinical cardiac dysfunction post-anti-cancer
treatment could potentially serve as a risk factor for COVID-
19-induced cardiac injury. Indeed, myocardial injury caused
by COVID-19 infection can worsen the outcome consequences
in patients with reduced cardiac reserve, leading to the
development of severe cardiac complications in these patients.
The cardiovascular complications from COVID-19 infection
could provoke an acceleration of the myocardial injury resulting
from anti-cancer treatment in a “two-hit” manner, as both
COVID-19 infection and anti-cancer therapy can lead to
myocardial injury (13). As mentioned previously, SARS-CoV-2
downregulates ACE2 expression by binding to ACE2 receptors
(47), and ACE2 receptors are essential regulators of cardiac
function (49). Therefore, in cancer patients and survivors that
have undertaken anti-cancer therapy, a COVID-19 infection
increases the potential for cardiac dysfunction due to the SARS-
CoV-2-induced downregulation of ACE2 receptor expression.
Further to this, the level of the cytokine storm modulator
interleukin IL-6 has shown to be increased in more severe cases
of COVID-19 compared to mild cases (55, 56). Interleukin
IL-6 is produced by tumor cells, and an elevated level of
IL-6 has been reported in various cancer types, such as lung
cancer (104), renal cell carcinoma (105), and ovarian cancer
(106). As a result of this, the elevated levels of IL-6 observed
in cancer patients and survivors can exacerbate the effect of
a potential COVID-19-mediated cytokine storm in infected
patients also through IL-6, which can lead to increased injury
in both lung (58) and myocardial tissue (59). On a positive
note, a Review by Vivarelli et al. based on preliminary case
studies with limited number of patients has hypothesized that
cancer patients treated with anti-PD-1 or anti-PD-L1 antibody
ICI therapy might potentially benefit from a boosted anti-viral
immune response in addition to the T-cell cytotoxic response
against cancer (107).
However, more studies are needed to get a better
understanding of intracellular cardiac injury mechanisms
due to COVID-19 infection and to unravel if these intracellular
mechanisms overlap with the anti-cancer drug-induced cardiac
injury pathways and mechanisms.
CONCLUSION
COVID-19 is a new challenge for cancer patients and survivors
treated with cardiotoxic anti-cancer drugs. Cancer patients and
survivors are immunocompromised and are therefore more
susceptible to develop severe complications resulting from
COVID-19 infection. In addition to targeting the respiratory
system and causing havoc in the lungs, COVID-19 can
induce cardiovascular complications and myocardial injury.
Understanding the pathways that lead to cardiac complications
during the COVID-19 infection can lead to the development of
more targeted and tailored therapy options in at-risk groups,
such as cancer patients and survivors, and thus improve the
outcome of vulnerable patient groups.
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